Which Indian pharmaceutical company announced the acquisition of the active pharmaceutical ingredients (API) business of Roche in Mexico?

Introduction / Context:
This question falls under business awareness and tests your knowledge of mergers and acquisitions in the global pharmaceutical industry. Specifically, it focuses on an Indian company that expanded its international footprint by acquiring the active pharmaceutical ingredients business of Roche in Mexico, an important event in the generics and API market.

Given Data / Assumptions:
- Roche is a well known multinational pharmaceutical company based in Switzerland.- The acquisition related to the active pharmaceutical ingredients, commonly abbreviated as API, produced in Mexico.- The acquiring firm is an Indian pharmaceutical company from the list in the options.- We assume standard knowledge of leading Indian pharma players like Wockhardt, Cipla, Dr Reddys Laboratories and Ranbaxy.

Concept / Approach:
To answer this question, you need to recall key business news about Indian pharma companies expanding abroad through acquisitions. Dr Reddys Laboratories has been particularly active in buying overseas assets to strengthen its API manufacturing and global generic drug presence. The acquisition of Roche's API business in Mexico was widely reported as part of this strategy. The other companies mentioned also engage in global business, but they were not associated with this specific deal.

Step-by-Step Solution:
Step 1: Recall which Indian companies are large, research driven and active in international acquisitions. Dr Reddys Laboratories is one of the best known names in this category.Step 2: Think of historical news related to Roche and Mexico. Business reports highlighted that Dr Reddys Laboratories acquired the Roche API facility and product portfolio in Mexico.Step 3: Evaluate Wockhardt, Cipla and Ranbaxy. While they have global operations, they were not reported as buyers of this particular Roche business.Step 4: Match the correct company name in the options. The one that fits the news event is Dr Reddys Laboratories.Step 5: Select option C as the correct answer.

Verification / Alternative check:
You can cross check by recalling that Dr Reddys Laboratories has a strong API division and a history of acquiring manufacturing facilities to secure supply and regulatory approvals in regulated markets. Major deals have included plants and product portfolios in Europe and Latin America. The acquisition in Mexico from Roche was consistent with its long term strategy to diversify geographically and improve cost competitiveness. No comparable headline about Wockhardt, Cipla or Ranbaxy acquiring a Roche API business in Mexico is commonly cited in standard business awareness sources.

Why Other Options Are Wrong:
Wockhardt: An important Indian pharmaceutical group, but it was not the buyer in the specific Roche API Mexico acquisition.Cipla: Known for respiratory and antiretroviral drugs and for global partnerships, yet not involved in this particular deal.Ranbaxy: Has made acquisitions abroad, especially in Europe, but the Mexico API business from Roche was not one of them.

Common Pitfalls:
Candidates often confuse different acquisition stories because many Indian pharma companies are active globally. A typical mistake is to choose a famous name at random without linking it to the specific event. Another pitfall is assuming that because Ranbaxy or Cipla are older or very visible, they must be the acquiring company. Focus on connecting the exact combination: Roche, API, Mexico and the correct Indian company which is Dr Reddys Laboratories.

Final Answer:
The Indian pharmaceutical company that acquired the Roche API business in Mexico is Dr Reddys Laboratories.